Literature DB >> 16318421

Potential of mesenchymal stem cells in gene therapy approaches for inherited and acquired diseases.

Jakob Reiser1, Xian-Yang Zhang, Charles S Hemenway, Debasis Mondal, Leena Pradhan, Vincent F La Russa.   

Abstract

The intriguing biology of stem cells and their vast clinical potential is emerging rapidly for gene therapy. Bone marrow stem cells, including the pluripotent haematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs) and possibly the multipotent adherent progenitor cells (MAPCs), are being considered as potential targets for cell and gene therapy-based approaches against a variety of different diseases. The MSCs from bone marrow are a promising target population as they are capable of differentiating along multiple lineages and, at least in vitro, have significant expansion capability. The apparently high self-renewal potential makes them strong candidates for delivering genes and restoring organ systems function. However, the high proliferative potential of MSCs, now presumed to be self-renewal, may be more apparent than real. Although expanded MSCs have great proliferation and differentiation potential in vitro, there are limitations with the biology of these cells in vivo. So far, expanded MSCs have failed to induce durable therapeutic effects expected from a true self-renewing stem cell population. The loss of in vivo self-renewal may be due to the extensive expansion of MSCs in existing in vitro expansion systems, suggesting that the original stem cell population and/or properties may no longer exist. Rather, the expanded population may indeed be heterogeneous and represents several generations of different types of mesenchymal cell progeny that have retained a limited proliferation potential and responsiveness for terminal differentiation and maturation along mesenchymal and non-mesenchymal lineages. Novel technology that allows MSCs to maintain their stem cell function in vivo is critical for distinguishing the elusive stem cell from its progenitor cell populations. The ultimate dream is to use MSCs in various forms of cellular therapies, as well as genetic tools that can be used to better understand the mechanisms leading to repair and regeneration of damaged or diseased tissues and organs.

Entities:  

Mesh:

Year:  2005        PMID: 16318421      PMCID: PMC1371057          DOI: 10.1517/14712598.5.12.1571

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  109 in total

1.  Effect of bone morphogenetic protein-12 gene transfer on mesenchymal progenitor cells.

Authors:  J Lou; Y Tu; F J Ludwig; J Zhang; P R Manske
Journal:  Clin Orthop Relat Res       Date:  1999-12       Impact factor: 4.176

Review 2.  Immunogenicity of adult mesenchymal stem cells: lessons from the fetal allograft.

Authors:  Frank P Barry; J Mary Murphy; Karen English; Bernard P Mahon
Journal:  Stem Cells Dev       Date:  2005-06       Impact factor: 3.272

Review 3.  Treatment of neurodegenerative diseases using adult bone marrow stromal cell-derived neurons.

Authors:  Mari Dezawa; Mikio Hoshino; Chizuka Ide
Journal:  Expert Opin Biol Ther       Date:  2005-04       Impact factor: 4.388

4.  Nonviral genetic modification mediates effective transgene expression and functional RNA interference in human mesenchymal stem cells.

Authors:  Juergen Hoelters; Marisa Ciccarella; Marei Drechsel; Claudia Geissler; Hülya Gülkan; Wolfgang Böcker; Matthias Schieker; Marianne Jochum; Peter Neth
Journal:  J Gene Med       Date:  2005-06       Impact factor: 4.565

5.  Multipotential marrow stromal cells transduced to produce L-DOPA: engraftment in a rat model of Parkinson disease.

Authors:  E J Schwarz; G M Alexander; D J Prockop; S A Azizi
Journal:  Hum Gene Ther       Date:  1999-10-10       Impact factor: 5.695

6.  Adenoviral-mediated gene transfer into ex vivo expanded human bone marrow mesenchymal progenitor cells.

Authors:  P A Conget; J J Minguell
Journal:  Exp Hematol       Date:  2000-04       Impact factor: 3.084

7.  Stable marker gene transfer into human bone marrow stromal cells and their progenitors using novel herpesvirus saimiri-based vectors.

Authors:  E A Frolova-Jones; A Ensser; A J Stevenson; S E Kinsey; D M Meredith
Journal:  J Hematother Stem Cell Res       Date:  2000-08

8.  Transplantation of gene-modified human bone marrow stromal cells into mouse-human bone chimeras.

Authors:  N Brouard; A Chapel; D Thierry; P Charbord; B Péault
Journal:  J Hematother Stem Cell Res       Date:  2000-04

9.  Long-term expression and transfer of arylsulfatase A into brain of arylsulfatase A-deficient mice transplanted with bone marrow expressing the arylsulfatase A cDNA from a retroviral vector.

Authors:  U Matzner; K Harzer; R D Learish; J A Barranger; V Gieselmann
Journal:  Gene Ther       Date:  2000-07       Impact factor: 5.250

10.  Long-term persistence of human bone marrow stromal cells transduced with factor VIII-retroviral vectors and transient production of therapeutic levels of human factor VIII in nonmyeloablated immunodeficient mice.

Authors:  M K Chuah; A Van Damme; H Zwinnen; I Goovaerts; V Vanslembrouck; D Collen; T VandenDriessche
Journal:  Hum Gene Ther       Date:  2000-03-20       Impact factor: 5.695

View more
  52 in total

1.  Extended and stable gene expression via nucleofection of MIDGE construct into adult human marrow mesenchymal stromal cells.

Authors:  P L Mok; S K Cheong; C F Leong; K H Chua; O Ainoon
Journal:  Cytotechnology       Date:  2011-12-10       Impact factor: 2.058

2.  2A peptide-based, lentivirus-mediated anti-death receptor 5 chimeric antibody expression prevents tumor growth in nude mice.

Authors:  Meng Li; Yaomin Wu; Yuhe Qiu; Zhenyu Yao; Shilian Liu; Yanxin Liu; Juan Shi; Dexian Zheng
Journal:  Mol Ther       Date:  2011-09-20       Impact factor: 11.454

3.  High-efficiency transduction of fibroblasts and mesenchymal stem cells by tyrosine-mutant AAV2 vectors for their potential use in cellular therapy.

Authors:  Mengxin Li; Giridhara R Jayandharan; Baozheng Li; Chen Ling; Wenqin Ma; Arun Srivastava; Li Zhong
Journal:  Hum Gene Ther       Date:  2010-10-06       Impact factor: 5.695

4.  A safe and efficient method to retrieve mesenchymal stem cells from three-dimensional fibrin gels.

Authors:  Bita Carrion; Isaac A Janson; Yen P Kong; Andrew J Putnam
Journal:  Tissue Eng Part C Methods       Date:  2013-08-14       Impact factor: 3.056

5.  Direct head-to-head comparison of cationic liposome-mediated gene delivery to mesenchymal stem/stromal cells of different human sources: a comprehensive study.

Authors:  Joana S Boura; Francisco Dos Santos; Jeffrey M Gimble; Carla M P Cardoso; Catarina Madeira; Joaquim M S Cabral; Cláudia Lobato da Silva
Journal:  Hum Gene Ther Methods       Date:  2013-02       Impact factor: 2.396

Review 6.  Stem cells for the treatment of musculoskeletal pain.

Authors:  Luminita Labusca; Florin Zugun-Eloae; Kaveh Mashayekhi
Journal:  World J Stem Cells       Date:  2015-01-26       Impact factor: 5.326

7.  Conditions to improve expansion of human mesenchymal stem cells based on rat samples.

Authors:  Maryam Ayatollahi; Maryam Kabir Salmani; Bita Geramizadeh; Seyed Ziaadin Tabei; Masoud Soleimani; Mohammad Hosein Sanati
Journal:  World J Stem Cells       Date:  2012-01-26       Impact factor: 5.326

8.  Generation and characterization of transgenic mouse mesenchymal stem cell lines expressing hIGF-1 or hG-CSF.

Authors:  Gabrielle V M Gonçalves; Daniela N Silva; Rejane H Carvalho; Bruno S F Souza; Kátia Nunes da Silva; Juliana F Vasconcelos; Bruno D Paredes; Carolina K V Nonaka; Ricardo Ribeiro-Dos-Santos; Milena B P Soares
Journal:  Cytotechnology       Date:  2017-09-02       Impact factor: 2.058

Review 9.  Mesenchymal stem cells as a treatment for peripheral arterial disease: current status and potential impact of type II diabetes on their therapeutic efficacy.

Authors:  Jinglian Yan; Guodong Tie; Ting Yu Xu; Katharine Cecchini; Louis M Messina
Journal:  Stem Cell Rev Rep       Date:  2013-06       Impact factor: 5.739

10.  Efficient lentiviral transduction of human mesenchymal stem cells that preserves proliferation and differentiation capabilities.

Authors:  Paul Lin; Yuan Lin; Donald P Lennon; Diego Correa; Mark Schluchter; Arnold I Caplan
Journal:  Stem Cells Transl Med       Date:  2012-11-29       Impact factor: 6.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.